1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
171.14 USD   -6.45%
05:41pNovavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08:10aEuropean Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
MT
07:36aNovavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BioNTech, Pfizer to starting testing universal coronavirus vaccine in H2

06/29/2022 | 08:00am EDT

June 29 (Reuters) - Germany's BioNTech, Pfizer's partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.

Their experimental work on shots that go beyond the current approach include T-cell enhancing shots, designed to primarily protect against severe disease if the virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.

The two partners, makers of the Western world's most widely used COVID-19 shot, are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its sublineages.

(Reporting by Ludwig Burger and Patricia Weiss)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -7.14% 157.21 Delayed Quote.-28.97%
MODERNA, INC. -6.45% 171.14 Delayed Quote.-26.44%
NOVAVAX, INC. -29.64% 40.28 Delayed Quote.-57.87%
PFIZER, INC. 0.42% 49.78 Delayed Quote.-16.56%
All news about MODERNA, INC.
05:41pNovavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
RE
08:10aEuropean Commission, Moderna Map Out COVID-19 Vaccine Rollout for Autumn, Summer
MT
07:36aNovavax tumbles 31% as waning COVID vaccine demand hits revenue forecast
RE
06:46aMODERNA : And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omic..
PU
06:41aModerna And the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omi..
EQ
08/08Novavax sinks after halving sales forecast on low vaccine demand, supply glut
RE
08/08BioNTech, Pfizer could deliver Omicron-adapted COVID-19 vaccines in October
AQ
08/08INSIDER SELL : Moderna
MT
08/08INSIDER SELL : Moderna
MT
08/08Climate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 21 875 M - -
Net income 2022 11 063 M - -
Net cash 2022 17 049 M - -
P/E ratio 2022 6,44x
Yield 2022 -
Capitalization 66 950 M 66 950 M -
EV / Sales 2022 2,28x
EV / Sales 2023 4,55x
Nbr of Employees 2 700
Free-Float 90,4%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 171,14 $
Average target price 214,00 $
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-26.44%71 566
LONZA GROUP AG-26.08%43 806
IQVIA HOLDINGS INC.-16.80%43 579
SEAGEN INC.13.72%32 890
ALNYLAM PHARMACEUTICALS, INC.28.89%27 695
CELLTRION, INC.6.82%21 572